Bank of New York Mellon Corp increased its position in AngioDynamics, Inc. (NASDAQ:ANGO)

Bank of New York Mellon Corp increased its position in AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) by 9.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 174,742 shares of the medical instruments supplier’s stock after acquiring an additional 15,412 shares during the period. Bank of New York Mellon Corp’s holdings in AngioDynamics were worth $1,057,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Fund 1 Investments LLC bought a new stake in AngioDynamics during the fourth quarter valued at approximately $3,896,000. ADAR1 Capital Management LLC purchased a new position in AngioDynamics in the fourth quarter valued at about $1,042,000. Kennedy Capital Management LLC boosted its position in shares of AngioDynamics by 425.0% in the first quarter. Kennedy Capital Management LLC now owns 190,236 shares of the medical instruments supplier’s stock worth $1,117,000 after acquiring an additional 154,002 shares during the period. Acadian Asset Management LLC boosted its stake in AngioDynamics by 11.9% in the first quarter. Acadian Asset Management LLC now owns 1,012,186 shares of the medical instruments supplier’s stock worth $5,940,000 after purchasing an additional 107,764 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of AngioDynamics by 9.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier’s stock valued at $199,000 after buying an additional 2,821 shares during the last quarter. 89.43% of shares are currently owned by institutional investors.

Analysts set new price targets

A number of brokerages have issued reports on ANGO. Canaccord Genuity Group cut their price target on AngioDynamics from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of AngioDynamics in a research note on Friday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.25, based on data from MarketBeat.com.

Read our latest review of AngioDynamics

AngioDynamics price performance

NASDAQ:ANGO opened at $7.54 on Friday. The company has a market cap of $302.01 million, a price-to-earnings ratio of -1.56 and a beta of 0.65. AngioDynamics, Inc. has a 1 year low of $5.26 and a 1 year high of $8.25. The stock’s 50-day simple moving average is $7.45, and its two-hundred-day simple moving average is $6.50.

AngioDynamics (NASDAQ:ANGO – Get Free Report ) last released its quarterly earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.11. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The company had revenue of $71.00 million for the quarter, compared to the consensus estimate of $70.86 million. In the same quarter last year, the firm earned $0.02 per share. AngioDynamics’ revenue fell 22.1% year over year. As a group, analysts anticipate that AngioDynamics, Inc. will post -0.41 EPS for the current year.

AngioDynamics profile

(Free Report)

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture and sale of medical, surgical and diagnostic devices for use in the treatment of peripheral vascular disease and oncology and surgical settings in the United States and internationally. The company offers the Auryon Atherectomy System that is designed to provide optimized wavelength, pulse width and amplitude to ablate lesions while preserving the vessel wall endothelium.

Featured stories

Want to see what other hedge funds ANGO owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for AngioDynamics, Inc. (NASDAQ:ANGO – Free Report).

Get news and reviews for AngioDynamics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AngioDynamics and related companies with MarketBeat.com ‘s FREE daily email newsletter.